You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 12, December 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tissue Plasminogen Activator Plus Glutamate Antagonist Improves Outcome After Embolic Stroke

Justin A. Zivin, MD, PhD; Vincent Mazzarella

Arch Neurol. 1991;48(12):1235-1238.


Abstract

• Thrombolytic therapy is likely to be effective in some patients with stroke, but further improvements may require combination treatment with neuroprotective agents that can be given rapidly with relative safety. We tested the effects of tissue plasminogen activator (t-PA) with the glutamate antagonist MK-801 or the calcium channel blocker nimodipine in an embolic stroke model. We found that MK-801, followed by t-PA, was more effective than t-PA alone in reducing neurologic damage. Nimodipine plus t-PA was not better than t-PA alone. Combined glutamate antagonist and thrombolytic therapy may provide increased efficacy and safety for stroke treatment.



Author Affiliations

From the Department of Neurosciences, University of California at San Diego, La Jolla.


Footnotes

Accepted for publication April 9, 1991.

Reprint requests to Department of Neurosciences 0624, University of California at San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0624 (Dr Zivin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Multimodal Neuroprotective Therapy With Induced Hypothermia After Ischemic Stroke
Hemmen and Lyden
Stroke 2009;40:S126-S128.
ABSTRACT | FULL TEXT  

Toward a Multimodal Neuroprotective Treatment of Stroke
Fisher et al.
Stroke 2006;37:1129-1136.
ABSTRACT | FULL TEXT  

Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions
Gladstone et al.
Stroke 2002;33:2123-2136.
ABSTRACT | FULL TEXT  

What have we learned from clinical neuroprotective trials?
Morgenstern
Neurology 2001;57:S45-47.
ABSTRACT | FULL TEXT  

An Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher and Schaebitz
Arch Intern Med 2000;160:3196-3206.
FULL TEXT  

Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
Stroke 1999;30:2752-2758.
ABSTRACT | FULL TEXT  

Thrombolytic stroke therapy: Past, present, and future
Zivin
Neurology 1999;53:14-14.
ABSTRACT | FULL TEXT  

Effects of Citicoline Combined With Thrombolytic Therapy in a Rat Embolic Stroke Model • Editorial Comment
Andersen et al.
Stroke 1999;30:1464-1471.
ABSTRACT | FULL TEXT  

Synergistic Effects of a Combination of Low-Dose Basic Fibroblast Growth Factor and Citicoline After Temporary Experimental Focal Ischemia • Editorial Comment
Schabitz et al.
Stroke 1999;30:427-432.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.